一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-110 号 一心堂药业集团股份有限公司 关于 2025 年前三季度计提信用减值及资产减值准备的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司(以下简称"公司")于2025年10月30日召开第六届董事会第 十八次会议，审议通过《关于2025年前三季度计提资产减值准备的议案》，根据相关规定，现 将具体情况公告如下： 一、本次计提减值准备情况概述 （一）本次计提减值准备的原因 根据《企业会计准则》《深圳证券交易所股票上市规则》及公司《财务管理制度》的相关 规定，为客观、公允、准确的反映公司截至2025年9月30日的财务状况、资产价值和2025年前三 季度的经营成果，公司对合并报表范围内截至2025年9月30日的各类资产进行了全面清查和充分 的评估分析，判断部分资产存在减值的迹象，需要计提减值准备。 （二）本次计提减值准备的资产范围和金额 公司进行清查和资产减值测试后，对部分资产计提资产减值准备，使得本年1-9月税前利润 减少人民币1,147.19万元。 ...

一心为民 全心服务 表决结果：同意 9 票，反对 0 票，弃权 0 票。 一心堂药业集团股份有限公司 第六届董事会第十八次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 一心堂药业集团股份有限公司(以下简称"公司")第六届董事会第十八次会议于2025年10 月30日10时以现场及通讯表决方式在公司会议室召开，本次会议于2025年10月17日通过邮件及 书面形式发出通知。本次会议应出席会议的董事为9人，实际出席会议的董事为9人。公司非董 事高级管理人员列席了会议。本次会议的召开符合有关法律、行政法规、部门规章、规范性文 件和《公司章程》的规定。会议由阮鸿献先生主持。与会董事逐项审议了有关议案并做出决议 如下。 二、董事会会议审议情况 1、审议通过《关于公司 2025 年第三季度报告的议案》 《2025 年第三季度报告》详见公司指定信息披露媒体《证券时报》《中国证券报》《证券 日报》和巨潮资讯网（www.cninfo.com.cn）。并批准 2025 年第三季度财务报告对外报出。 股票代码：002727 股票简称：一心堂 公告 ...

Financial Performance - The company's revenue for Q3 2025 was ¥4,086,535,700.64, representing a decrease of 4.62% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥18,941,635.48, an increase of 78.71% year-on-year, while net profit excluding non-recurring items was ¥9,935,344.15, down 78.04%[5]. - The company reported a basic earnings per share of ¥0.0324, an increase of 82.02% year-on-year[5]. - Total operating revenue for the current period is CNY 13,001,028,971.88, a decrease of 4.3% from CNY 13,589,430,513.51 in the previous period[26]. - Net profit for the current period is CNY 279,953,869.97, a decline of 8.7% compared to CNY 306,673,555.30 in the previous period[27]. - Earnings per share (EPS) for the current period is CNY 0.4587, down from CNY 0.4908 in the previous period[27]. Assets and Liabilities - The total assets at the end of the reporting period were ¥15,841,053,806.65, a decrease of 5.88% from the end of the previous year[5]. - The company's total assets decreased from 16,830,316,478.61 CNY to 15,841,053,806.65 CNY[24]. - The total liabilities decreased from 7,631,183,301.72 CNY to 6,979,005,378.72 CNY[24]. - Total liabilities amount to CNY 8,371,468,517.29, a decrease from CNY 9,177,027,604.21[25]. - Total equity attributable to shareholders of the parent company is CNY 7,317,083,552.48, down from CNY 7,491,014,022.79[25]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥1,432,091,712.35, reflecting a growth of 15.42%[5]. - Operating cash inflow for the current period was CNY 12,704,003,248.60, a decrease of 3.49% from CNY 13,165,397,205.14 in the previous period[28]. - Net cash flow from operating activities increased to CNY 1,432,091,712.35, up 15.43% from CNY 1,240,746,217.23 year-on-year[28]. - Cash inflow from investment activities totaled CNY 2,467,651,564.49, significantly higher than CNY 221,281,983.49 in the previous period[28]. - Cash inflow from financing activities was CNY 580,060,000.00, an increase from CNY 457,060,000.00 in the previous period[29]. - Net cash flow from financing activities was negative at CNY -1,139,973,371.69, an improvement from CNY -1,309,261,172.78 year-on-year[29]. Investments and Expenditures - The company increased its investment in other equity instruments by 272.86%, totaling ¥13,050,000.00, due to new investments and adjustments in existing holdings[9]. - The construction in progress increased by 210.73% to ¥111,198,725.40, driven by multiple ongoing projects including digital manufacturing bases[10]. - Cash paid for operating activities was CNY 11,271,911,536.25, a decrease from CNY 11,924,650,987.91 in the previous period[28]. - Total cash outflow for investment activities was CNY 2,417,100,285.50, compared to CNY 599,520,771.70 in the previous period[28]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 37,494[15]. - The largest shareholder, 阮鸿献, holds 31.12% of the shares, amounting to 182,245,290 shares[15]. - The company approved a cash dividend of 2 CNY per 10 shares, totaling 114,825,645 CNY (including tax) for the 2025 interim profit distribution[18]. Business Segments and Operations - The traditional Chinese medicine segment focuses on developing innovative products in the food and medicine integration field, enhancing product standardization and convenience[19]. - The first centralized healthcare center achieved breakeven within two years, with a second center under construction expected to open in the first half of 2026[20]. - The non-pharmaceutical business segment has completed the upgrade of 805 stores, with significant growth driven by the health and wellness category, maintaining high double-digit growth in the first three quarters of 2025[21].

Core Viewpoint - YXTT experienced a slight decline of 0.93% on October 29, with a trading volume of 76.68 million yuan, indicating a low financing balance relative to its market value [1][2]. Financing Summary - On October 29, YXTT had a financing buy-in amount of 9.95 million yuan and a financing repayment of 7.95 million yuan, resulting in a net financing buy of 1.99 million yuan. The total financing and securities balance reached 226 million yuan, which is 2.79% of its market value, indicating a low level compared to the past year [1]. - The financing balance of 226 million yuan is below the 50th percentile level over the past year, suggesting a conservative financing approach [1]. Securities Lending Summary - On the same day, YXTT repaid 700 shares and sold 500 shares in securities lending, with a selling amount of 6,905 yuan. The remaining securities lending volume was 53,500 shares, with a balance of 738,800 yuan, also below the 40th percentile level over the past year [1]. Company Overview - YXTT, established on November 8, 2000, and listed on July 2, 2014, is based in Kunming, Yunnan Province. The company primarily engages in pharmaceutical retail and wholesale, with its revenue composition being 75.03% from Western and Chinese medicines, 9.86% from other products, 8.56% from traditional Chinese medicine, and 6.55% from medical devices and disinfectants [1]. Financial Performance - For the first half of 2025, YXTT reported a revenue of 8.914 billion yuan, a year-on-year decrease of 4.20%, and a net profit attributable to shareholders of 250 million yuan, down 11.44% year-on-year [2]. - Since its A-share listing, YXTT has distributed a total of 2.023 billion yuan in dividends, with 764 million yuan distributed over the past three years [2]. Shareholder Structure - As of June 30, 2025, YXTT had 33,900 shareholders, a decrease of 5.42% from the previous period, with an average of 11,712 circulating shares per shareholder, an increase of 5.73% [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited as the third-largest shareholder, holding 18.5744 million shares, a decrease of 21.1993 million shares from the previous period. New entrants among the top shareholders include several mutual funds from GF Securities [3].

Group 1 - The core viewpoint of the article is that Yixin Tang is leveraging its subsidiary Yixin Convenience to enhance its business model by integrating health and convenience store operations [2] Group 2 - Yixin Convenience is a wholly-owned subsidiary of Yixin Tang, focusing on the convenience store business [2] - The company aims to create a synergistic effect between its convenience stores and pharmacies through a "health + convenience" model [2]

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-107 号 一心堂药业集团股份有限公司 关于全资子公司重庆鸿翔一心堂药业有限公司 向银行申请授信额度提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 一心堂药业集团股份有限公司(以下简称"公司")本次为全资子公司重庆鸿翔一心堂药业 有限公司（以下简称"重庆一心堂"或"债务人")提供连带责任保证方式的担保，被担保企业 重庆一心堂最近一期经审计（2024年12月31日）的资产负债率超过70%，敬请投资者充分关注担 保风险。 一、担保情况概述 公司于 2024 年 12 月 13 日召开 2024 年度第三次临时股东大会，审议通过《关于同意子公 司向相关银行申请综合授信额度并为其提供担保的议案》，同意公司担保下属子公司向相关银 行申请综合授信共计 13.68 亿元，用于子公司融资业务，具体额度在不超过 13.68 亿元的金额 上限内以银行授信为准，以上综合授信的金额在一年内以银行授信为准。《关于同意子公司向 相关银行申请综合授信额度并为其提供担保的公告》详 ...

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-106 号 一心堂药业集团股份有限公司 关于公司股东阮鸿献先生部分股票质押融资 到期还款解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司（以下简称"公司"）近日接到公司股东阮鸿献先生通知， 获悉阮鸿献先生与广发证券股份有限公司（以下简称"广发证券"）达成协议，将 2022 年 11 月 1 日及 2022 年 11 月 7 日向广发证券申请办理的股票质押融资业务进行到期还款并解除股票 质押，具体事项如下： 一、股东股份质押情况 1、股份质押解除情况 | 股东名称 | 是否为控股 股东或第一 | 本次解除质 押股份数量 | 占其所持 | 占公司 总股本 | 起始日 | 解除日期 | 质权人/申 请人等 | 备注 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 大股东及其 一致行动人 | （万股） | 股份比例 | 比例 | | | | | | 阮鸿献 | 是 | 4 ...

Core Points - YXTT Pharmaceutical Group Co., Ltd. has proposed amendments to its Articles of Association, which will be submitted for shareholder approval [1][3][43] - The amendments are based on relevant laws and regulations, including the Company Law of the People's Republic of China and the Shenzhen Stock Exchange Listing Rules [1][3] - The company will hold its third extraordinary general meeting of 2025 on November 13, 2025, to discuss the proposed amendments and other matters [7][8][38] Summary of Amendments - The specific changes to the Articles of Association have been outlined in a comparison table, with other provisions remaining unchanged [2] - The amendments will be subject to final approval by the relevant administrative authorities [3] Meeting Details - The extraordinary general meeting will be held on November 13, 2025, at 14:00, with both on-site and online voting options available [7][8][9] - Shareholders must register to attend the meeting, with the registration deadline set for November 12, 2025 [17][18][19] - Voting will be conducted using a cumulative voting system for certain proposals, requiring a two-thirds majority for special resolutions and a simple majority for ordinary resolutions [15][16][38] Board of Directors Election - The company will elect its seventh board of directors, consisting of nine members, including five non-independent directors and three independent directors [67][68] - The candidates for the non-independent and independent director positions have been nominated and will be presented for shareholder voting [67][68][39][40]

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-105 号 一心堂药业集团股份有限公司 一、股东股份质押情况 | 1、股份质押基本情况 | | --- | | | 是否为 控股股 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 东或第 | 本次质 | 占其所 | | 是否为限 售股（如 | 是否 为补 | | | 质权 | | | 股东名 | 一大股 | 押数量 | 持股份 | 占公司总 | | | 质押起始日 | 质押到期日 | | 质押用途 | | 称 | 东及其 | （万股） | 比例 | 股本比例 | 是，注明限 | 充质 | | | 人 | | | | 一致行 | | | | 售类型） | 押 | | | | | | | 动人 | | | | | | | | | | | 阮鸿献 | 是 | 309 | 1.695% | 0.53% | 否 | 否 | 2025-10-27 | 2026-10-27 | 广发 | 置换股票 | | | ...

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-103 号 一心堂药业集团股份有限公司 关于使用部分暂时闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司(以下简称"公司")于2025年5月21日召开2024年年度股东会， 审议通过《关于使用部分暂时闲置自有资金进行现金管理的议案》，同意公司及全资子公司使 用额度不超过人民币25亿元的闲置自有资金进行现金管理（包括但不限于购买一年期以内的固 定收益型或保本浮动收益型理财产品、大额存单、定期存款、通知存款、协定存款等），相关 额度在投资期限内任一时点的现金管理金额(含前述投资的收益进行再投资的相关金额)不超过 25亿元人民币。在上述额度内，资金可以滚动使用，在额度范围内授权董事长具体办理实施相 关事项。 一、本次进行现金管理基本情况 近日，公司与广发银行股份有限公司昆明万宏支行签订了《广发银行人民币结构性存款合 同》，本次进行现金管理基本情况如下： | 签约银行 | 产品名称 | 认购金额 | 收益类型 | 合同起始日 ...